front page - LESI connectWelcome to the LES Community

Collaborate here with LES members globally -- share strategic advice, solve challenges and develop new approaches to help you effectively license and monetize intellectual property.



Discover committees and engage in our community to enrich your experience and learning opportunities.




Find others with whom you may seek advice and share common challenges.




Join in discussions with LES members and industry leaders to expand your knowledge.


Recommended for You

  • Either the content you're seeking doesn't exist or it requires proper authentication before viewing.
  • Quick Links


    Unanswered Questions

    • LinkedIN ... Reply

    • Save ... Reply

    • Join ... Reply

    Upcoming Events

    • Wednesday

      LESI Innovation Trends Committee "Creating Innovation: Meet the Winners of the 2023 LESI Innovation

      Dec 6, 17:00 - 18:00 (CET)
      Innovation is key for any good and healthy company. During the webinar, we will meet some of the winners of the 2023 LESI Innovation Award to understand which factors drive innovation and how innovative companies move from an idea to a product. The cases presented will be of great inspiration for both innovators and people advising companies on innovative processes and IP. Speakers: Antonio Di Bernardo and Tanja Sovic – Innovation Trends Committee Chairs Rupa H Darji - BASF Corporation Lisa Schroeder - BASF Corporation Julian Bobe - CIRC

    • Thursday

      LESI Thought Leadership Program 2023/24 - Track 3: UPC Litigation Strategies

      Dec 7, 17:00 - 18:30 (CET)
      Join us for the next session in the Track 2 of LESI’s Thought Leadership Program: UPC Litigation Strategies. This is session # 2 and will feature an interview with two UPC Judges: Dr. Matthias Zigann - Presiding Judge of the Local Division of the UPC Court in Munich Mrs. Rian Kalden - Presiding Judge of the second panel and member of the Presidium of the UPC

    • Tuesday

      LES USA-Canada "Yescarta: A Journey from Development to Licensing"

      Dec 12, 14:00 - 15:00 (ET)
      The presentation will address two topics related to licensing efforts of the National Cancer Institute (NCI). The first, a case study on the CAR-T product axicabtagene ciloleucel (sold under the brand name Yescarta®), will cover the development history of this ground-breaking therapy from the NCI technology transfer perspective. The second will be a brief discussion of NCI’s exclusive licensing practices as they concern important technologies in the adoptive cell therapy space. This will touch on how the NCI leverages federal licensing statute (e.g., 37 CFR § 404) to maximize utilization and public benefit of these inventions. Speaker: Andrew Burke, Senior Technology Transfer Manager, National Cancer Institute

    Most Active Members